Witnessing the stock’s movement on the chart, on Thursday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had a quiet start as it plunged -4.03% to $46.89, before settling in for the price of $48.86 at the close. Taking a more long-term approach, RARE posted a 52-week range of $37.02-$60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 63.06%. Meanwhile, its Annual Earning per share during the time was -15.75%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 24.09%. This publicly-traded company’s shares outstanding now amounts to $92.24 million, simultaneously with a float of $83.32 million. The organization now has a market capitalization sitting at $4.33 billion. At the time of writing, stock’s 50-day Moving Average stood at $50.74, while the 200-day Moving Average is $48.09.
Ultragenyx Pharmaceutical Inc (RARE) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Ultragenyx Pharmaceutical Inc’s current insider ownership accounts for 9.77%, in contrast to 92.12% institutional ownership. According to the most recent insider trade that took place on Dec 10 ’24, this organization’s President & CEO sold 8,273 shares at the rate of 50.00, making the entire transaction reach 413,650 in total value, affecting insider ownership by 2,195,712.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
Ultragenyx Pharmaceutical Inc’s EPS increase for this current 12-month fiscal period is 24.09% and is forecasted to reach -5.10 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 37.90% through the next 5 years, which can be compared against the -15.75% growth it accomplished over the previous five years trading on the market.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Let’s observe the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). It’s Quick Ratio in the last reported quarter now stands at 2.65. The Stock has managed to achieve an average true range (ATR) of 1.77. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.28.
In the same vein, RARE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.46, a figure that is expected to reach -1.34 in the next quarter, and analysts are predicting that it will be -5.10 at the market close of one year from today.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Going through the that latest performance of [Ultragenyx Pharmaceutical Inc, RARE]. Its last 5-days volume of 0.68 million was inferior to the volume of 0.77 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 61.09% While, its Average True Range was 1.79.
Raw Stochastic average of Ultragenyx Pharmaceutical Inc (RARE) in the period of the previous 100 days is set at 22.22%, which indicates a major fall in contrast to 31.35% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.23% that was lower than 37.84% volatility it exhibited in the past 100-days period.
